Occident Group

Lymphatica Medtech SA is a Swiss company that specializes in the design and manufacture of medical devices aimed at treating lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed innovative solutions such as the LymphoDrain system, which includes an active implantable lymphatic bypass that integrates a magnetically controlled micropump and subcutaneous catheters. This technology is designed to re-establish lymphatic circulation by internally draining lymphatic fluid from multiple points in the affected limb, providing a minimally invasive remedy for patients suffering from lymphedema. Lymphatica Medtech's commitment to advancing treatment options in this field reflects its focus on improving patient outcomes through cutting-edge medical technology.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

InSphero specializes in the production and application of organotypic 3D cell culture models for various applications. It offers a range of assay-ready microtissues derived from liver, pancreas, tumor, heart, brain, and skin cells, along with optimized media and platforms for their generation and cultivation. The company's products include human and rat liver microtissues, pancreatic microislets, tumor microtissues, custom-made microtissues, cytotoxicity assay kits, and a human liver disease discovery platform. InSphero also provides services such as hepatotoxicity testing, oncology service packs, and embryonic stem cell test services. Its 3D InSight microtissues are used in toxicity testing, drug metabolism studies, cancer research, stem cell research, and disease modeling.

Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

iMusician Digital AG is a Swiss-based online platform founded in 2007, dedicated to empowering musicians in managing, selling, and monetizing their music. Located in Zurich, the company offers a comprehensive suite of tools that enables artists to distribute their music across major streaming services and sales platforms. iMusician focuses on simplifying the process for musicians by providing real-time sales tracking and copyright management, allowing them to concentrate on their creative work. With a small, passionate international team, iMusician Digital strives to support artists in navigating the complexities of the music industry and maximizing their revenue potential.

InSphero specializes in the production and application of organotypic 3D cell culture models for various applications. It offers a range of assay-ready microtissues derived from liver, pancreas, tumor, heart, brain, and skin cells, along with optimized media and platforms for their generation and cultivation. The company's products include human and rat liver microtissues, pancreatic microislets, tumor microtissues, custom-made microtissues, cytotoxicity assay kits, and a human liver disease discovery platform. InSphero also provides services such as hepatotoxicity testing, oncology service packs, and embryonic stem cell test services. Its 3D InSight microtissues are used in toxicity testing, drug metabolism studies, cancer research, stem cell research, and disease modeling.

iMusician Digital AG is a Swiss-based online platform founded in 2007, dedicated to empowering musicians in managing, selling, and monetizing their music. Located in Zurich, the company offers a comprehensive suite of tools that enables artists to distribute their music across major streaming services and sales platforms. iMusician focuses on simplifying the process for musicians by providing real-time sales tracking and copyright management, allowing them to concentrate on their creative work. With a small, passionate international team, iMusician Digital strives to support artists in navigating the complexities of the music industry and maximizing their revenue potential.